KDM1A and acute myeloid leukemia: In early-phase clinical trials, LSD1 inhibitors showed only modest activity in Acute Myeloid Leukemia (AML) [13–15], indicating that effective combination therapy approaches will be required to achieve clinically meaningful responses in aggressive myeloid blood cancers.